Patents by Inventor Hachiro Sugimoto
Hachiro Sugimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220031787Abstract: The problems to be solved by the present invention are to provide a novel agent for preventing and/or treating a neurodegenerative disease, and a pharmaceutical composition comprising the agent for preventing and/or treating a neurodegenerative disease. The problems are solved by providing an agent for preventing and/or treating a neurodegenerative disease, the agent comprising as an active ingredient an extract of Momordica charantia var. pavel, and preferably the agent is for use in treatment or prevention of a disease selected from Alzheimer's disease, Parkinson's disease, Down syndrome, tauopathy (for example, argyrophilic grain dementia, senile dementia of neurofibrillary tangle type, progressive supranuclear palsy, degeneration of cerebral cortex or Pick disease), and dementia with lewy bodies.Type: ApplicationFiled: November 12, 2019Publication date: February 3, 2022Applicants: GREEN TECH CO., LTD., McB.,Co.Inventors: Hachiro SUGIMOTO, Koki NAGASHIMA, Michiaki OKUDA, Yuki FUJITA
-
Publication number: 20210393551Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.Type: ApplicationFiled: September 1, 2021Publication date: December 23, 2021Inventors: Akihiko TAKASHIMA, Yoshiyuki SOEDA, Hiroyuki OSADA, Yasuo IHARA, Tomohiro MIYASAKA, Hachiro SUGIMOTO
-
Publication number: 20180161288Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.Type: ApplicationFiled: February 12, 2018Publication date: June 14, 2018Inventors: Akihiko TAKASHIMA, Yoshiyuki SOEDA, Hiroyuki OSADA, Yasuo IHARA, Tomohiro MIYASAKA, Hachiro SUGIMOTO
-
Patent number: 9907799Abstract: A tau aggregation inhibitor can sufficiently inhibit a tau protein from aggregating in cells. The inhibitor includes a 4-substituted catechol structure compound, having, at position 4 of its catechol ring, an electron-donating substituent R other than a hydrocarbon group, or a salt thereof. The 4-substituted catechol structure compound is preferably 4-aminocatechol or 1,2,4-benzenetriol. Examples of tauopathies to which this inhibitor is applicable include AD, Down's syndrome, frontotemporal dementia, cotricobasal degeneration (CBD) and progressive supranuclear palsy (PSP).Type: GrantFiled: April 2, 2014Date of Patent: March 6, 2018Assignees: THE DOSHISHA, National Center for Geriatrics and GerontologyInventors: Tomohiro Miyasaka, Hachiro Sugimoto, Rie Tokizane, Yuki Shinzaki, Yohei Oe, Tetsuo Ota, Akihiko Takashima, Yoshiyuki Soeda, Yasuo Ihara, Yoshikazu Inoue
-
Patent number: 9724333Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): or a salt thereof.Type: GrantFiled: April 19, 2016Date of Patent: August 8, 2017Assignee: GREEN TECH CO., LTD.Inventors: Hachiro Sugimoto, Michiaki Okuda, Shinichi Nakayama, Yoshikazu Inoue, Yoko Sakata, Yuki Fujita, Rie Tokizane
-
Publication number: 20160228412Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): or a salt thereof.Type: ApplicationFiled: April 19, 2016Publication date: August 11, 2016Inventors: Hachiro Sugimoto, Michiaki Okuda, Shinichi Nakayama, Yoshikazu Inoue, Yoko Sakata, Yuki Fujita, Rie Tokizane
-
Patent number: 9399635Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): [wherein Ar1 represents 2-methoxy-4-(2-pyridylmethoxy)phenyl etc. and Ar2 represents a 1H-indol-6-yl group etc.] or a salt thereof.Type: GrantFiled: April 11, 2012Date of Patent: July 26, 2016Assignee: GREEN TECH CO., LTD.Inventors: Hachiro Sugimoto, Michiaki Okuda, Takashi Takahashi, Ichiro Hijikuro, Hidetaka Suzuki, Shinichi Nakayama
-
Patent number: 9321752Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): or a salt thereof.Type: GrantFiled: September 17, 2013Date of Patent: April 26, 2016Assignee: GREEN TECH CO., LTD.Inventors: Hachiro Sugimoto, Michiaki Okuda, Shinichi Nakayama, Yoshikazu Inoue, Yoko Sakata, Yuki Fujita, Rie Tokizane
-
Publication number: 20160030437Abstract: A tau aggregation inhibitor can sufficiently inhibit a tau protein from aggregating in cells. The inhibitor includes a 4-substituted catechol structure compound, having, at position 4 of its catechol ring, an electron-donating substituent R other than a hydrocarbon group, or a salt thereof. The 4-substituted catechol structure compound is preferably 4-aminocatechol or 1,2,4-benzenetriol. Examples of tauopathies to which this inhibitor is applicable include AD, Down's syndrome, frontotemporal dementia, cotricobasal degeneration (CBD) and progressive supranuclear palsy (PSP).Type: ApplicationFiled: April 2, 2014Publication date: February 4, 2016Inventors: Tomohiro Miyasaka, Hachiro Sugimoto, Rie Tokizane, Yuki Shinzaki, Yohei Oe, Tetsuo Ota, Akihiko Takashima, Yoshiyuki Soeda, Yasuo Ihara, Yoshikazu Inoue
-
Publication number: 20150252029Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): or a salt thereof.Type: ApplicationFiled: September 17, 2013Publication date: September 10, 2015Inventors: Hachiro Sugimoto, Michiaki Okuda, Shinichi Nakayama, Yoshikazu Inoue, Yoko Sakata, Yuki Fujita, Rie Tokizane
-
Patent number: 8987486Abstract: An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.Type: GrantFiled: November 1, 2011Date of Patent: March 24, 2015Assignees: Nagoya Industrial Science Research Institute, Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomonori Matsumoto, Hachiro Sugimoto
-
Patent number: 8962674Abstract: The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on A? aggregation, a degradative effect on A? aggregates, an inhibitory effect on ?-secretase, and a protective effect on neurons. The novel compound is a compound represented by the following general formula (Ia) or a salt thereof: wherein R1 represents a 4-hydroxy-3-methoxyphenyl group or the like, and R2 represents a 1H-indol-6-yl group or the like.Type: GrantFiled: November 30, 2007Date of Patent: February 24, 2015Assignees: Tokyo Institute of Technology, Kyoto UniversityInventors: Takashi Takahashi, Ichiro Hijikuro, Hachiro Sugimoto, Takeshi Kihara, Yoshiari Shimmyo, Tetsuhiro Niidome
-
Publication number: 20140249180Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.Type: ApplicationFiled: October 3, 2012Publication date: September 4, 2014Applicants: National Center for Geriatrics and Gerontology, THE DOSHISHAInventors: Akihiko Takashima, Yoshiyuki Soeda, Hiroyuki Nagata, Yasuo Ihara, Tomohiro Miyasaka, Hachiro Sugimoto
-
Patent number: 8686024Abstract: The present invention provides a novel indoline derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or a salt thereof represented by the following formula (1) that has an excellent butyrylcholinesterase inhibitory activity. In the formula, R1 represents an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an arylalkyl group, a heteroarylalkyl group, a cycloalkylalkyl group, a heterocycloalkylalkyl group, a dihydrofurylalkyl group, an alkenyl group, a tetrahydronaphthyl group, or an indanyl group; R2 represents a hydrogen atom, an alkyl group, an arylalkyl group, a cycloalkylalkyl group, a heteroarylalkyl group, a heterocycloalkylalkyl group, an aryl group, or an acyl group; R3 each independently represents a hydrogen atom, an alkyl group, or a dialkylaminocarbonyl group; R4 each independently represents a hydrogen atom or an alkyl group; and R5 represents a hydrogen atom or an alkyl group.Type: GrantFiled: February 3, 2010Date of Patent: April 1, 2014Assignees: Kyoto University, Tokyo Institute of TechnologyInventors: Hachiro Sugimoto, Jun Takahashi, Takashi Takahashi, Ichiro Hijikuro
-
Publication number: 20140088029Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): [wherein Ar1 represents 2-methoxy-4-(2-pyridylmethoxy)phenyl etc. and Ar2 represents a 1H-indol-6-yl group etc.] or a salt thereof.Type: ApplicationFiled: April 11, 2012Publication date: March 27, 2014Applicant: PHARMA EIGHT CO., LTD.Inventors: Hachiro Sugimoto, Michiaki Okuda, Takashi Takahashi, Ichiro Hijikuro, Hidetaka Suzuki, Shinichi Nakayama
-
Patent number: 8552220Abstract: To develop a highly safe measure to treat Alzheimer's disease using a secretase-inhibiting substance, there is provided a compound represented by the following general formula (I) or a salt thereof: wherein A represents a phenyl group or the like, R1 represents a chlorine atom, a bromine atom, or a nitro group or the like, R2, R3, R4, and R5 each represent a hydrogen atom or the like, and L represents CH2—CH2 or CH?CH.Type: GrantFiled: May 27, 2009Date of Patent: October 8, 2013Assignees: Tokyo Institute of Technology, Kyoto UniversityInventors: Hachiro Sugimoto, Takashi Takahashi, Ichiro Hijikuro, Michiaki Okuda
-
Publication number: 20130225837Abstract: An object of the present invention is to provide a novel trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof and to provide a pharmaceutical agent which contains said compound as an active ingredient and has a highly safe neurotrophic factor-like activity or an alleviating action for side effect induced by administration of anti-cancer agents. The trans-2-decenoic acid derivative or a pharmaceutically acceptable salt thereof which is the compound of the present invention is specifically represented by the formula (1): (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group) and has a quite high usefulness as a pharmaceutical agent such as a preventive or therapeutic agent for dementia, Alzheimer's disease, Parkinson's disease, depression, etc., a treating or repairing agent for spinal cord injury.Type: ApplicationFiled: November 1, 2011Publication date: August 29, 2013Applicants: Nippon Zoki Pharmaceutical Co., Ltd., Nagoya Industrial Science Research InstituteInventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomonori Matsumoto, Hachiro Sugimoto
-
Publication number: 20110294850Abstract: The present invention provides a novel indoline derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or a salt thereof represented by the following formula (1) that has an excellent butyrylcholinesterase inhibitory activity. In the formula, R1 represents an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an arylalkyl group, a heteroarylalkyl group, a cycloalkylalkyl group, a heterocycloalkylalkyl group, a dihydrofurylalkyl group, an alkenyl group, a tetrahydronaphthyl group, or an indanyl group; R2 represents a hydrogen atom, an alkyl group, an arylalkyl group, a cycloalkylalkyl group, a heteroarylalkyl group, a heterocycloalkylalkyl group, an aryl group, or an acyl group; R3 each independently represents a hydrogen atom, an alkyl group, or a dialkylaminocarbonyl group; R4 each independently represents a hydrogen atom or an alkyl group; and R5 represents a hydrogen atom or an alkyl group.Type: ApplicationFiled: February 3, 2010Publication date: December 1, 2011Applicants: TOKYO INSTITUTE OF TECHNOLOGY, KYOTO UNIVERSITYInventors: Hachiro Sugimoto, Jun Takahashi, Takashi Takahashi, Ichiro Hijikuro
-
Publication number: 20110082295Abstract: To develop a highly safe measure to treat Alzheimer's disease using a secretase-inhibiting substance, there is provided a compound represented by the following general formula (I) or a salt thereof: wherein A represents a phenyl group or the like, R1 represents a chlorine atom, a bromine atom, or a nitro group or the like, R2, R3, R4, and R5 each represent a hydrogen atom or the like, and L represents CH2—CH2 or CH?CH.Type: ApplicationFiled: May 27, 2009Publication date: April 7, 2011Applicants: Tokyo Institute of Technology, Kyoto UniversityInventors: Hachiro Sugimoto, Takashi Takahashi, Ichiro Hijikuro, Michiaki Okuda
-
Publication number: 20100048901Abstract: The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on A? aggregation, a degradative effect on A? aggregates, an inhibitory effect on ?-secretase, and a protective effect on neurons. The novel compound is a compound represented by the following general formula (Ia) or a salt thereof: wherein R1 represents a 4-hydroxy-3-methoxyphenyl group or the like, and R2 represents a 1H-indol-6-yl group or the like.Type: ApplicationFiled: November 30, 2007Publication date: February 25, 2010Applicants: TOKYO INSTITUTE OF TECHNOLOGY, Kyoto UniversityInventors: Takashi Takahashi, Ichiro Hijikuro, Hachiro Sugimoto, Takeshi Kihara, Yoshiari Shimmyo, Tetsuhiro Niidome